Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
MetaVia ( (MTVA) ) has provided an announcement.
On January 15–16, 2026, MetaVia Inc. completed an underwritten public offering of Class A and Class B units, consisting of common stock, pre-funded warrants and Series C and Series D common warrants, raising approximately $7.7 million in net proceeds after discounts and expenses from gross proceeds of about $8.1 million. The transaction, led by Ladenburg Thalmann & Co. Inc., included full exercise of the underwriter’s over-allotment option and established a package of fixed-price, immediately exercisable warrants, some of which are subject to beneficial ownership limits and potential future callability tied to positive Phase 1b Part III data for DA-1726; MetaVia plans to deploy the capital for working capital and general corporate purposes, notably to advance clinical development of DA-1726 for obesity, reinforcing its funding base and strategic focus in the competitive cardiometabolic drug development arena.
The most recent analyst rating on (MTVA) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
Spark’s Take on MTVA Stock
According to Spark, TipRanks’ AI Analyst, MTVA is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and worsening cash burn) and bearish technicals (well below major moving averages with negative MACD). Offsetting this, recent positive clinical-trial milestones and regained Nasdaq compliance improve the outlook, but not enough to overcome current funding and trend risks.
To see Spark’s full report on MTVA stock, click here.
More about MetaVia
MetaVia Inc., based in Cambridge, Massachusetts, is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. Its lead candidate, DA-1726, is a novel oxyntomodulin analogue acting as a dual GLP1R and GCGR agonist in development for obesity, while vanoglipel (DA-1241) is a GPR119 agonist being developed for Metabolic Dysfunction-Associated Steatohepatitis (MASH), with both programs supported by prior Phase 1 and Phase 2a data indicating potential benefits in weight loss, glucose control and liver health.
Average Trading Volume: 225,512
Technical Sentiment Signal: Strong Sell
Current Market Cap: $12.51M
For detailed information about MTVA stock, go to TipRanks’ Stock Analysis page.